American-Chinese CEO Society
    Event & Membership Site

ACCS UCLA CWH Joint Symposium on Healthcare Investments & Collaboration

  • 18 Jan 2017
  • 1:30 PM - 4:30 PM
  • Ronald Reagan UCLA Medical Center 757 Westwood Plaza Los Angeles, CA 90095


  • Non-member

Registration is closed


   ACCS UCLA CWH Joint Symposium on Healthcare Investments & Collaboration

Time:          January 18th 2017  1:30 pm to 4:30 pm          

Location:   Tamkin Auditorium

                    Ronald Reagan UCLA Medical Center

                    757 Westwood Plaza Los Angeles, CA 90095

Topics:   A) Investments in healthcare

                B) Ways that UCLA evaluates new technologies

                C) Collaboration with healthcare investors on  

                     Next-generation scientific breakthroughs

                    D)  Advances in cancer treatment

VIP Speakers:



              Weili Zhou, President


                Amphora Capital Group


  • 1-       Intro on major causes of death and disability in China: Dr. Thomas Coates
  • 2-       Advances in cancer treatment: Dr. Judith Gasson
  • 3-       Telepathology: Dr. Scott Binder & Dr. Rao Jianyu
  • 4-       Technology transfer and intellectual property management.: Earl Weinstein
  • 5-       Health systems consulting and international patient services: Michael Burke and Vivian Beene


Thomas J. Coates, Ph.D.


Dr. Coates is the Director of the UCLA Center for World Health and the UCLA Program in Global Health and is also the Michael and Sue Steinberg Endowed Professor of Global AIDS Research within the Division of Infectious Diseases at UCLA. In 1986, Dr. Coates co-founded the Center for AIDS Prevention Studies (CAPS) at UCSF and directed it from 1991 to 2003. He was also the founding Executive Director of the UCSF AIDS Research Institute, leading it from 1996 to 2003.  His areas of emphasis and expertise are HIV prevention, the relationship of prevention and treatment for HIV, and HIV policies. Dr. Coates has conducted research on HIV/STI prevention among most-at-risk populations in urban Peru for the past decade, including the Peru site of the NIH-funded Community Popular Opinion (CPOL) trial and the currently ongoing Comunidades Positivas (CPOS) trial of community-based HIV/STI prevention. He continues his HIV prevention research in sub-Saharan Africa (Malawi, South Africa, Uganda), Latin America (Peru), and Asia (China).  He personally supervises the Directors of the on-the-ground offices in Malawi (Mr. John Hamilton), Cape Town (Ms. Laurie Bruns), and Peru (Dr. Jesse Clark).  He has also mentored numerous postdoctoral and early career investigators over the course of their career, many of whom have continued on to become leaders in the field of HIV/STI prevention.  He was elected to the Institute of Medicine of the National Academy of Sciences in 2000.


Michael Burke, MHA


Michael is the Director of UCLA Health International and Director of Business Development for the UCLA Center for World Health.  In addition to overseeing UCLA Health’s incoming international patient population, he is responsible for seeking out and vetting potential partnership opportunities for the medical enterprise while advancing existing partnerships and collaborations.  Since joining the Center in 2014, his focus has been developing a strategy to build capacity in Asia and abroad without limiting local resources.  Michael joined UCLA Health as a 2012-2013 Administrative Fellow where his worked focused largely on value and performance improvement initiatives. He received his undergraduate degree in finance and his Master in Health Administration from the University of Iowa. Prior to joining UCLA, he completed an administrative residency at Kameda Medical Center in Kamogawa-shi, Japan where he focused on Joint Commission International, pain assessment and awareness, and evaluation of international patient traffic.  


https://people.healthsciences.ucla.edu/hsc-umb/institution/photo?personnel%5fid=46712 Judith Gasson, Ph.D.


Judith C. Gasson, a professor of biological chemistry and medicine, became director of UCLA’s Jonsson Comprehensive Cancer Center on Sept. 15, 1995. A molecular biologist, Gasson is responsible for one of only 39 institutions nationwide designated as comprehensive cancer centers by the National Cancer Institute. In addition to her administrative duties, Gasson also is a gifted scientist. She was instrumental in purifying for the first time a hormone-like substance that increases the speed of bone marrow cell reproduction. That substance, called GM-CSF, is used to help prevent infections in cancer patients, and to allow patients to tolerate more chemotherapy and radiation than had previously been possible. In 2005, Gasson was named a co-director of the UCLA Institute of Stem Cell Biology and Medicine and she recently testified before a key Senate subcommittee on the promise of stem cell research in cancer. Gasson also serves as a board member for the American Association for Cancer Research. She earned a bachelor?s degree in microbiology from Colorado State University and a doctorate in physiology at the University of Colorado. Gasson did post doctoral work at the Salk Institute in La Jolla. In 1983, she left the Salk Institute to join UCLA's Jonsson Cancer Center, which comprises more than 240 researchers and clinicians engaged in research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson center is dedicated to promoting research and translating the results into leading-edge clinical studies. In July 2005, the Jonsson Cancer Center was named the best cancer center in the western United States by U.S. News & World Report, a ranking it has held for six consecutive years.


https://www.uclahealth.org/pictures/PNRS/Jian-Yu-Rao.jpg Jian Yu Rao, M.D.


Dr. J Rao is a diagnostic surgical/cytopathologist and established investigator in cancer biomarker studies. Prior to be a pathologist, he was already an established molecular epidemiologist involved in multiple high profile cancer prevention studies. He completed his anatomic/clinical pathology residency and cytopathology fellowship at UCLA, and joined the UCLA Department of Pathology as a faculty in 1999.

Dr. J. Rao is a full professor and the chief of Cytopathology, ex-director of gynecological pathology, the director of international telepathology, and the medical director of cytotechnology school. He has dual appointments in pathology and epidemiology. He is also a recipient of Thousand-Talent program of China. He is particularly well known for cancer biomarker studies, as he has over 30 year experience in this area. He has been invited to be a speaker for over 100 meetings and occasions locally, nationally and internationally for topics including urine cytology, Fine Needle Aspiration cytology, gynecological pathology, and cancer molecular biomarkers. Dr. Rao has an active role in teaching and research, with continuous funding from NIH or other agencies for cancer biomarker and prevention studies in the last 25 years, with over 140 peer-reviewed research publications. He is also interested in developing new technologies for pathology especially cytopathology, including imaging analysis, nanotechnology and telepathology.



The UCLA Center for World Health and the American-Chinese CEO Society Partner to Present a Discussion on Cutting-Edge Health Care Technologies and Innovations.

With increasing incidence and mortality, cancer is the leading cause of death in China. Many types of cancer are not detected early enough, and many cancer deaths could be prevented by increasing the effectiveness of clinical care delivery.

On Wednesday January 18th, UCLA experts, led by Dr. Thomas Coates, Director of the UCLA Center for World Health, will discuss recent advances in cancer research as well as ways in which UCLA incubates new technologies and develops intellectual property.

In addition, the long-term strategic alliance between UCLA Health and Chinese institutions will be highlighted. The goal of these partnerships is to enhance the provision of medical care in China. Examples include the formation of a regional Tele-Pathology center of excellence, the establishment of visionary medical education centers as well as the strengthening of public and private health systems.

     Come to meet 20 member of China Healthcare Investor's Delegation to discuss business opportunity!  

Christopher Moulding

Christopher Moulding is the Associate Director in the Office of Technology Licensing at City of Hope.  Chris has been involved in Tech Transfer for over 25 years, having held licensing positions at UCLA, Caltech, Howard Hughes Medical Institute, and the University of Southern California.  Chris began his career working as a research associate at Harvard Medical School and NIH, and thereafter he earned an MBA from Stanford Business School.  He worked at Genentech, Chiron, and Systemix in business development, and was a co-founder of Recombinant Capital, a financial advisory services company.

Linda Malkas

Ph.D. M.T.  & B.A. Ahmadinia Professor in Molecular Oncology Deputy Director of Basic Research and Co-leader, Womens Cancers Programs, Comprehensive Cancer Center  Professor and Associate Chairman of Molecular and Cellular Biology 

Linda H. Malkas is currently professor and associate chair of the Department of Molecular and Cellular Biology at the Beckman Research Institute of City of Hope, serving as the deputy director of basic research. In 2011, she co-founded the Molecular Oncology Program at the cancer center. 

 Dr. Malkas received her B.A. in chemistry and Ph.D. in biochemistry from the City University of New York. She completed her post-doctoral studies at the Worchester Foundation for  Experimental Biology in Massachusetts, and held faculty positions at the University of Maryland School Of Medicine in Baltimore. Before joining City of Hope, she was at the Indiana University School of Medicine as a Professor of Medicine and the Universitys first Vera Bradley Chair in Oncology. While there, she co-founded and served as co-leader of the Indiana University Simon Cancer Centers Breast Cancer Research Program.  She also founded and served as the first Director of the Signature Center for Breast Cancer Research at Indiana University. 

Yuan Chen

 Beckman Research Institute of the City of Hope

Professor Chen, graduated from the University of Science and Technology of China in 1985 with a Ph.D. in Chemistry from Rutgers University in 1992. He received his PhD in Chemistry from the University of Science and Technology of China. After completing his postdoctoral work at the laboratory of Peter Wright of the Scripps Research Institute, he began tenure at City of Hope in 1994. Her laboratory focuses on research and discovery of new anti-cancer mechanisms and new drug development. Her research has been supported by research funding from the National Institutes of Health (NIH), which has many years of experience leading research projects to success.

Yong QIAN Ph.D

Dr QIAN is the president of BioMedicure Group,having been a senior scientist of GeneCure and Access Business GroupDr QIAN received his Ph.D in University and post-Ph.D in University of Kentucky. Dr. Qian has extensive research in the field of new antigenic immunology for genomics, and has obtained many US patents.

Qin PU Ph.D

Dr PU, graduated from the  Nankai University with bachelor degree in chemistry Biology, and from the 4th Military Medical University with Ph.D in chemistry biology .Working in Biomedical Engineering of Genomics for more than 20 years, having constructed an advanced genetic engineering  platform, his main research areas are gene-based biotechnology, bio-chemical engineering, bioinformatics, Engineering technology platform and the re-understanding of a variety of complex diseases genetic engineering vaccine.

Sanjeev Saxena

CEO of POC Medical Systemes ,30 + years of experience in starting and running  companies, engineering, salesmarketing and  business development for medical device and Biotech companies,Founder of Actis Biologics, Telesto Diagnostics (In India  and Malaysia respectively), Co-founder of Scanis, Sepragen Corp .

"Ginnie" Xin Xu, Ph.D.

"Ginnie" Xin Xu, Ph.D. is a Technology Licensing Manager at City of Hope. Ginnie joined City of Hope in 2016. Previously Ginnie has worked at tech transfer offices at University of Southern California and Rutgers University. She holds a Ph.D. from Princeton University in Molecular Biology and Neuroscience; and a B.S. from Fudan University in Life Sciences.


Viona Zhang 张嘉倩

Project Director 项目总监

American- Chinese CEO Society


Mobile: 626-466-6833

Twitter: AmChCEO  Facebook: 企业家
Youtube: www.youtube.com/channel/UCGxxS38COiffPWDCWoCSt9Q 
Youku: 美中企业家商会

© American-Chinese CEO Society
Powered by Wild Apricot Membership Software